Asset Dedication LLC Purchases 1,940 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Asset Dedication LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 43.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,421 shares of the biopharmaceutical company’s stock after purchasing an additional 1,940 shares during the quarter. Asset Dedication LLC’s holdings in Gilead Sciences were worth $593,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bellevue Group AG raised its stake in Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after purchasing an additional 7,093 shares in the last quarter. Quantinno Capital Management LP raised its position in shares of Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after buying an additional 48,910 shares in the last quarter. IRON Financial LLC bought a new stake in shares of Gilead Sciences in the third quarter valued at approximately $830,000. Capital Investment Advisors LLC grew its position in Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after buying an additional 9,791 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in Gilead Sciences by 12.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock worth $27,081,000 after acquiring an additional 36,895 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the topic of several analyst reports. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. UBS Group raised their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Finally, Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 456,234 shares of company stock valued at $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 1.9 %

Shares of Gilead Sciences stock opened at $95.59 on Thursday. The stock’s 50-day moving average is $92.00 and its 200 day moving average is $85.44. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The firm has a market cap of $119.13 billion, a price-to-earnings ratio of 1,062.11, a PEG ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.29 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.